Crucell Announces PER.C6® Licensing Agreement with Edwards Lifesciences
26-Nov-2004 -
Dutch biotechnology company Crucell N.V. has signed a PER.C6® research license agreement with Edwards Lifesciences Corporation. The non-exclusive agreement allows Edwards to use the PER.C6® cell line for research and development of gene therapeutics based on adenoviral vectors. Under the terms of ...
biotechnology
cardiovascular diseases
cell lines
+2